2023
Neurologic Complications of Babesiosis, United States, 2011–2021 - Volume 29, Number 6—June 2023 - Emerging Infectious Diseases journal - CDC
Locke S, O’Bryan J, Zubair A, Rethana M, Moffarah A, Krause P, Farhadian S. Neurologic Complications of Babesiosis, United States, 2011–2021 - Volume 29, Number 6—June 2023 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2023, 29: 1127-1135. PMID: 37209667, PMCID: PMC10202888, DOI: 10.3201/eid2906.221890.Peer-Reviewed Original ResearchConceptsNeurologic complicationsNeurologic symptomsRisk factorsYale-New Haven HospitalInfectious Diseases journal - CDCHigh-grade parasitemiaNeurologic risk factorsRange of symptomsAdult patientsRenal failureDiabetes mellitusFrequent symptomsHospital admissionImpaired consciousnessMedical recordsEndemic areasParasitic infectionsPatientsSymptomsIntraerythrocytic protozoaComplicationsBabesiosisNew HavenDeliriumMellitus
2022
Cardiac Complications of Human Babesiosis
Spichler-Moffarah A, Ong E, O’Bryan J, Krause PJ. Cardiac Complications of Human Babesiosis. Clinical Infectious Diseases 2022, 76: e1385-e1391. PMID: 35983604, PMCID: PMC10169432, DOI: 10.1093/cid/ciac525.Peer-Reviewed Original ResearchConceptsYale-New Haven HospitalCardiac complicationsRisk factorsIntensive care unit stayCardiovascular disease risk factorsHuman babesiosisCommon cardiac complicationHigh-grade parasitemiaLife-threatening complicationsDisease risk factorsLonger median lengthQT interval prolongationHigh mortality rateUnit stayComplication groupTick-borne diseaseAdult patientsCardiac outcomesMost patientsThin blood smearsHeart failureInterval prolongationModerate illnessRecord reviewAtrial fibrillation
2019
Immunoepidemiology of Immune Dysfunction
Meffre E, Krause P, Ruddle N. Immunoepidemiology of Immune Dysfunction. 2019, 127-148. DOI: 10.1007/978-3-030-25553-4_8.ChaptersFood allergyAutoimmune diseasesIgE antibodiesRisk factorsPathogenic mechanismsImmediate hypersensitivity diseasesNon-IgE antibodiesIntravenous immunoglobulin therapySystemic lupus erythematosusBone marrow transplantationPrimary immune deficiencyT cell selectionAcquired etiologiesImmunoglobulin therapyHypersensitivity diseasesImmune dysfunctionLupus erythematosusFood intoleranceInfluence of lifestyleMarrow transplantationRheumatoid arthritisHLA typesImmune deficiencyLymphoproliferative syndromeTreatment strategies
1994
Quality Standard for the Treatment of Bacteremia
Gross P, Barrett T, Dellinger E, Krause P, Martone W, McGowan J, Sweet R, Wenzel R. Quality Standard for the Treatment of Bacteremia. Infection Control And Hospital Epidemiology 1994, 15: 189-192. DOI: 10.2307/30145559.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsQuality Standards SubcommitteeInfectious Diseases SocietyTreatment of bacteremiaDiseases SocietyBlood culturesChart reviewersAdverse outcomesPediatric Infectious Diseases SocietyPlacebo-controlled trialPresence of bacteremiaSurgical Infection SocietySerious adverse outcomesAdministration of antibioticsAppropriate antimicrobial treatmentClinical Affairs CommitteeCase-control studyPositive blood culturesSpecific clinical indicationsAppropriate dosingHospitalized patientsRenal failureClinical trialsRisk factorsClinical indicationsHospital epidemiologyQuality standard for the treatment of bacteremia. The Infectious Diseases Society of America.
Gross P, Barrett T, Dellinger E, Krause P, Martone W, McGowan J, Sweet R, Wenzel R. Quality standard for the treatment of bacteremia. The Infectious Diseases Society of America. Infection Control And Hospital Epidemiology 1994, 15: 189-92. PMID: 8207177, DOI: 10.1086/646888.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsInfectious Diseases SocietyQuality Standards SubcommitteeTreatment of bacteremiaDiseases SocietyBlood culturesChart reviewersAdverse outcomesPediatric Infectious Diseases SocietyPlacebo-controlled trialPresence of bacteremiaSerious adverse outcomesSurgical Infection SocietyAdministration of antibioticsAppropriate antimicrobial treatmentClinical Affairs CommitteeCase-control studyPositive blood culturesSpecific clinical indicationsAppropriate dosingRenal failureHospitalized patientsProlonged hospitalizationRisk factorsClinical indicationsClinical trials